Rohan Khera, Arya Aminorroaya, Lovedeep Singh Dhingra, Phyllis M Thangaraj, Aline Pedroso Camargos, Fan Bu, Xiyu Ding, Akihiko Nishimura, Tara V Anand, Faaizah Arshad, Clair Blacketer, Yi Chai, Shounak Chattopadhyay, Michael Cook, David A Dorr, Talita Duarte-Salles, Scott L DuVall, Thomas Falconer, Tina E French, Elizabeth E Hanchrow, Guneet Kaur, Wallis Cy Lau, Jing Li, Kelly Li, Yuntian Liu, Yuan Lu, Kenneth Kc Man, Michael E Matheny, Nestoras Mathioudakis, Jody-Ann McLeggon, Michael F McLemore, Evan Minty, Daniel R Morales, Paul Nagy, Anna Ostropolets, Andrea Pistillo, Thanh-Phuc Phan, Nicole Pratt, Carlen Reyes, Lauren Richter, Joseph Ross, Elise Ruan, Sarah L Seager, Katherine R Simon, Benjamin Viernes, Jianxiao Yang, Can Yin, Seng Chan You, Jin J Zhou, Patrick B Ryan, Martijn J Schuemie, Harlan M Krumholz, George Hripcsak, Marc A Suchard
BACKGROUND: SGLT2 inhibitors (SGLT2is) and GLP-1 receptor agonists (GLP1-RAs) reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes mellitus (T2DM). However, their effectiveness relative to each other and other second-line antihyperglycemic agents is unknown, without any major ongoing head-to-head trials. METHODS: Across the LEGEND-T2DM network, we included ten federated international data sources, spanning 1992-2021. We identified 1,492,855 patients with T2DM and established cardiovascular disease (CVD) on metformin monotherapy who initiated one of four second-line agents (SGLT2is, GLP1-RAs, dipeptidyl peptidase 4 inhibitor [DPP4is], sulfonylureas [SUs])...
February 8, 2024: medRxiv